Market Synopsis:
The fertility
drug and surgery market share is expected to reach USD 2.21 billion by 2030
at 9.50% CAGR during the forecast period 2022-2030.The rates of infertility are
getting higher, which has encouraged massive investments in the research &
development of effective drugs and surgeries. Market Research Future (MRFR) has
highlighted in its latest analysis that the global fertility drug and surgery
market is projected to expand at a CAGR of 9.8% during the projection period of
2018 to 2023.
Infertility diseases affect both men and women. Treatments
have been developed for both the genders and drug research is expected to
constantly drive the expansion of the fertility drug and surgery market over
the next couple of years. In addition, rising working population of women has
led to increased cases of late pregnancies. This, in turn, is prognosticated to
boost the revenue creation of the fertility drug and surgery market over the
next couple of years.
Obesity is also a significant factor driving the growth of
the market. Increasing burden of obesity has led to an exponential increase in
the prevalence of infertility. It is projected to catapult the global fertility
drug and surgery market on an upward trajectory over the forecast period. Other
factors such as increasing disposable income, rising healthcare expenditure,
etc. are poised to influence the market positively. However, on the flip side,
factors such as high treatment cost and complications associated with surgeries
is anticipated to restrict market growth over the next few years.
Market Segmentation:
Based on the underlying cause, the global fertility
drug and surgery market outlook has been segmented into male and female.
By drug, the fertility drug and surgery market has been
segmented into letrozole, Serophene, clomiphene citrate, hormone treatment,
gonadotrophins estrogen receptor modulators, aromatase inhibitors, dopamine
agonists, metformin hydrochloride, and others.
Depending on the procedures, the global fertility drug and
surgery market has been segmented into laparoscopy and robotic laparoscopy,
hysteroscopy, laparotomy/open surgery, varicocelectomy, vasectomy reversal
(vasovasostomy or vasoepididymostomy), egg retrieval, sperm retrieval
(epididymal aspiration).
Based on end-user, the fertility drug and surgery market has
been segmented into hospitals, clinical research institutes, fertility clinics,
and others.
Regional Analysis:
A detailed geographical analysis of the global fertility
drug and surgery market has been included in this MRFR report which covers four
major regions – Americas, Asia Pacific, Europe, and the Middle East &
Africa (MEA). Americas is likely to lead the expansion of the market on account
of the increasing rate of infertility in the region. Rising prevalence of
obesity and increasing cases of delayed pregnancies are anticipated to catapult
the global fertility drug and surgery market on upward trajectory in the years
to come. Europe held the second leading position in 2017. It has been studied
in this report that the riding prevalence of sexually transmitted diseases is
responsible for increasing infertility rate in the region. On the other hand,
Asia Pacific fertility drug and surgery market is poised to exhibit immense
developments. Factors such as rising awareness, availability of healthcare
services, etc. are projected to boost revenue growth of the fertility drug and
surgery market in the region over the next few years.
Competitive Dashboard:
The key players participating in the landscape of the global
fertility drug and surgery market are Eli Lilly, Baxter Healthcare Corporation,
Ferring Pharmaceuticals, Inc., Merck & Co. Pharmaceutical Company, Noven
Pharmaceuticalorganon, Inc., Janssen Pharmaceuticals Inc., Personal Products
Company, Pfizer, Inc., Procter & Gamble Pharmaceuticals, and Emd Serono,
Inc. Growth strategies are expected to e executed by these players that are
poised to boost revenue creation in the market over the next couple of years.
Few of these strategies are mergers & acquisitions, collaborations,
partnerships, etc. Investments are also anticipated to be injected in the
future trajectory of the fertility drug and surgery market for gaining edge
over competitors.
The Wall